Chronic Spontaneous Urticaria and Bruton Tyrosine Kinase: A Multispecialty Expert Discussion : Episode 9

Opinion

Video

March 6, 2025

CSU Burden of Disease and Quality of Life

Author(s):

Giselle Mosnaim, MD, MS ,Shyam Joshi, MD

Panelists discuss how chronic spontaneous urticaria (CSU) significantly impacts patients’ quality of life through persistent itching, unpredictable flares, sleep disruption, emotional distress, and daily activity limitations, underscoring the need for effective disease control.

EP: 1.Chronic Spontaneous Urticaria and Bruton Tyrosine Kinase: A Multispecialty Expert Discussion

EP: 2.Pathophysiology of Chronic Spontaneous Urticaria

EP: 3.Current CSU Treatment Approach and the Role of Bruton Tyrosine Kinase

EP: 4.BTK Inhibition as a Strategy for CSU Treatment

EP: 5.How BTK Inhibitors Differ From Current CSU Treatment Approaches

EP: 6.Overview of BTK Inhibitors in Development for CSU Treatment

EP: 7.Differentiating BTK Inhibition From Genetic BTK Deficiency

EP: 8.Overview of Remibrutinib Phase 3 Clinical Trials in CSU

EP: 9.CSU Burden of Disease and Quality of Life

Related Videos

Confirming Tapinarof’s Efficacy and Safety Across Atopic Dermatitis Severities, with Justin Greiwe, MD

Investigating Briquilimab’s Efficacy and Safety for CSU, with Thomas Casale, MD

What to Look Forward to at the American Academy of Dermatology Annual Meeting 2025

Ahmad Anouti, MD | Credit: UT Southwestern

Kent Lam I Credit: Macon & Joan Brock Virigina Health Sciences at Old Dominion University

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.